Literature DB >> 26715125

Cardiac ACE2/angiotensin 1-7/Mas receptor axis is activated in thyroid hormone-induced cardiac hypertrophy.

Gabriela P Diniz1, Nathalia Senger1, Marcela S Carneiro-Ramos2, Robson A S Santos3, Maria Luiza M Barreto-Chaves4.   

Abstract

OBJECTIVES: Thyroid hormone (TH) promotes marked effects on the cardiovascular system, including the development of cardiac hypertrophy. Some studies have demonstrated that the renin-angiotensin system (RAS) is a key mediator of the cardiac growth in response to elevated TH levels. Although some of the main RAS components are changed in cardiac tissue on hyperthyroid state, the potential modulation of the counter regulatory components of the RAS, such as angiotensin-converting enzyme type 2 (ACE2), angiotensin 1-7 (Ang 1-7) levels and Mas receptor induced by hyperthyroidism is unknown. The aim of this study was to investigate the effect of hyperthyroidism on cardiac Ang 1-7, ACE2 and Mas receptor levels.
METHODS: Hyperthyroidism was induced in Wistar rats by daily intraperitoneal injections of T4 for 14 days.
RESULTS: Although plasma Ang 1-7 levels were unchanged by hyperthyroidism, cardiac Ang 1-7 levels were increased in TH-induced cardiac hypertrophy. ACE2 enzymatic activity was significantly increased in hearts from hyperthyroid animals, which may be contributing to the higher Ang 1-7 levels observed in the T4 group. Furthermore, elevated cardiac levels of Ang 1-7 levels were accompanied by increased Mas receptor protein levels.
CONCLUSION: The counter-regulatory components of the RAS are activated in hyperthyroidism and may be contributing to modulate the cardiac hypertrophy in response to TH.
© The Author(s), 2015.

Entities:  

Keywords:  Mas receptor; angiotensin 1–7; angiotensin-converting enzyme type 2; thyroid hormone

Mesh:

Substances:

Year:  2015        PMID: 26715125      PMCID: PMC5942623          DOI: 10.1177/1753944715623228

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN: 1753-9447


  49 in total

1.  Interaction between Mas and the angiotensin AT1 receptor in the amygdala.

Authors:  O Von Bohlen und Halbach; T Walther; M Bader; D Albrecht
Journal:  J Neurophysiol       Date:  2000-04       Impact factor: 2.714

2.  Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism.

Authors:  H Kobori; A Ichihara; H Suzuki; T Takenaka; Y Miyashita; M Hayashi; T Saruta
Journal:  Am J Physiol       Date:  1997-08

Review 3.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

4.  Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.

Authors:  JiuChang Zhong; Ratnadeep Basu; Danny Guo; Fung L Chow; Simon Byrns; Manfred Schuster; Hans Loibner; Xiu-hua Wang; Josef M Penninger; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circulation       Date:  2010-08-02       Impact factor: 29.690

5.  G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor.

Authors:  Evi Kostenis; Graeme Milligan; Arthur Christopoulos; Carlos F Sanchez-Ferrer; Silvia Heringer-Walther; Patrick M Sexton; Florian Gembardt; Elaine Kellett; Lene Martini; Patrick Vanderheyden; Heinz-Peter Schultheiss; Thomas Walther
Journal:  Circulation       Date:  2005-04-04       Impact factor: 29.690

6.  Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats.

Authors:  Jennifer Lo; Vaibhav B Patel; Zuocheng Wang; Jody Levasseur; Susan Kaufman; Josef M Penninger; Gavin Y Oudit
Journal:  Exp Physiol       Date:  2012-06-29       Impact factor: 2.969

Review 7.  An update of the role of renin angiotensin in cardiovascular homeostasis.

Authors:  Ehab Farag; Kamal Maheshwari; Joseph Morgan; Wael Ali Sakr Esa; D John Doyle
Journal:  Anesth Analg       Date:  2015-02       Impact factor: 5.108

8.  Plasma angiotensin(1-7) immunoreactivity is increased by salt load, water deprivation, and hemorrhage.

Authors:  L M Botelho; C H Block; M C Khosla; R A Santos
Journal:  Peptides       Date:  1994       Impact factor: 3.750

Review 9.  A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology.

Authors:  Pitchai Balakumar; Gowraganahalli Jagadeesh
Journal:  Cell Signal       Date:  2014-07-05       Impact factor: 4.315

10.  Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway.

Authors:  Bei Song; Zhen-Zhou Zhang; Jiu-Chang Zhong; Xi-Yong Yu; Gavin Y Oudit; Hai-Yan Jin; Lin Lu; Ying-Le Xu; Zamaneh Kassiri; Wei-Feng Shen; Ping-Jin Gao; Ding-Liang Zhu
Journal:  Circ J       Date:  2013-10-26       Impact factor: 2.993

View more
  5 in total

Review 1.  Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22.

Authors:  Sadashiva S Karnik; Khuraijam Dhanachandra Singh; Kalyan Tirupula; Hamiyet Unal
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

Review 2.  The prognostic values of thyroid disorders in predicting COVID-19 composite poor outcomes: A systematic review and meta-analysis.

Authors:  Hikmat Permana; Erwin Affandi Soeriadi; Fachreza Aryo Damara; Nanny Natalia Mulyani Soetedjo
Journal:  Diabetes Metab Syndr       Date:  2022-03-18

Review 3.  Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2.

Authors:  Francesca Salamanna; Melania Maglio; Maria Paola Landini; Milena Fini
Journal:  Front Med (Lausanne)       Date:  2020-12-03

Review 4.  SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves' disease.

Authors:  Avaniyapuram Kannan Murugan; Ali S Alzahrani
Journal:  Endocrine       Date:  2021-06-09       Impact factor: 3.633

Review 5.  COVID-19 and Thyroid Diseases: A Bidirectional Impact.

Authors:  Leonidas H Duntas; Jacqueline Jonklaas
Journal:  J Endocr Soc       Date:  2021-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.